Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duravelo-2: BT8009 alone or with pembrolizumab versus chemotherapy followed by avelumab in advanced urothelial carcinoma
MOH_2024-07-02_013491Phase 3Recruiting
- Sponsor
- Bicycle Therapeutics
- Start
- Jun 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zelenectide pevedotin in transitional cell carcinoma (TCC) (6 cohorts), sponsored by Bicycle Therapeutics. Started Jun 2024; status: recruiting.
02
Drugs
zelenectide pevedotin
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on MOH_2024-07-02_013491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-07-02_013491.